Clemens Krepler

9.9k total citations · 4 hit papers
75 papers, 4.2k citations indexed

About

Clemens Krepler is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Clemens Krepler has authored 75 papers receiving a total of 4.2k indexed citations (citations by other indexed papers that have themselves been cited), including 60 papers in Oncology, 47 papers in Molecular Biology and 15 papers in Immunology. Recurrent topics in Clemens Krepler's work include Melanoma and MAPK Pathways (34 papers), CAR-T cell therapy research (32 papers) and Cancer Immunotherapy and Biomarkers (32 papers). Clemens Krepler is often cited by papers focused on Melanoma and MAPK Pathways (34 papers), CAR-T cell therapy research (32 papers) and Cancer Immunotherapy and Biomarkers (32 papers). Clemens Krepler collaborates with scholars based in United States, Australia and Spain. Clemens Krepler's co-authors include Meenhard Herlyn, Min Xiao, Katherine L. Nathanson, Georgina V. Long, Matteo S. Carlino, Caroline Robert, Jean‐Jacques Grob, Adina Vultur, Patricia Brafford and Ana Arance and has published in prestigious journals such as Nature, Journal of Clinical Oncology and PLoS ONE.

In The Last Decade

Clemens Krepler

72 papers receiving 4.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study

2019 768 citations Caroline Robert, Antoni Ribas et al. profile →
Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance

2017 756 citations Clemens Krepler, Katrin Sproesser et al. profile →
Overcoming Intrinsic Multidrug Resistance in Melanoma by Blocking the Mitochondrial Respiratory Chain of Slow-Cycling JARID1Bhigh Cells

2013 487 citations Alexander Roesch, Adina Vultur et al. profile →
Enhancing CD8+ T Cell Fatty Acid Catabolism within a Metabolically Challenging Tumor Microenvironment Increases the Efficacy of Melanoma Immunotherapy

2017 481 citations Xiaowei Xu, Giorgos C. Karakousis et al. profile →

Peers

Clemens Krepler

ONCOL

IMMUN

PRM

Willy Hugo United States

Hetal Patel United Kingdom

Michael Hölzel Germany

Uwe Trefzer Germany

Norma O’Donovan Ireland

Begonya Comin-Anduix United States

Rita Nahta United States

Lev Demidov Russia

Kimberly B. Dahlman United States

Harshani R. Lawrence United States

Willy Hugo United States

Clemens Krepler

2.5k ×1.0

2.4k ×1.0

ONCOL

1.4k ×1.3

IMMUN

644 ×0.9

442 ×1.3

PRM

Citations per year, relative to Clemens Krepler Clemens Krepler (= 1×) peers Willy Hugo

Countries citing papers authored by Clemens Krepler

Since Specialization

Citations

This map shows the geographic impact of Clemens Krepler's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Clemens Krepler with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Clemens Krepler more than expected).

Fields of papers citing papers by Clemens Krepler

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Clemens Krepler. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Clemens Krepler. The network helps show where Clemens Krepler may publish in the future.

Co-authorship network of co-authors of Clemens Krepler

This figure shows the co-authorship network connecting the top 25 collaborators of Clemens Krepler. A scholar is included among the top collaborators of Clemens Krepler based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Clemens Krepler. Clemens Krepler is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Weber, Jeffrey S., Jason J. Luke, Matteo S. Carlino, et al.. (2024). INTerpath-001: Pembrolizumab with V940 (mRNA-4157) versus pembrolizumab with placebo for adjuvant treatment of high-risk stage II-IV melanoma.. Journal of Clinical Oncology. 42(16_suppl). TPS9616–TPS9616. 9 indexed citations

Luke, Jason J., Paolo A. Ascierto, Muhammad A. Khattak, et al.. (2024). Pembrolizumab Versus Placebo as Adjuvant Therapy in Resected Stage IIB or IIC Melanoma: Final Analysis of Distant Metastasis-Free Survival in the Phase III KEYNOTE-716 Study. Journal of Clinical Oncology. 42(14). 1619–1624. 43 indexed citations

Schadendorf, Dirk, Jason J. Luke, Paolo A. Ascierto, et al.. (2024). Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Outcomes in histopathologic subgroups from the randomized, double-blind, phase 3 KEYNOTE-716 trial. Journal for ImmunoTherapy of Cancer. 12(3). e007501–e007501. 5 indexed citations

Leachman, Sancy A., Jason J. Luke, Paolo A. Ascierto, et al.. (2024). 53808 Adjuvant Pembrolizumab Versus Placebo in Stage IIB or IIC Melanoma: Exploratory Post Hoc Analyses of Patients with New Primary Melanoma and Other Skin Cancers from the Phase 3 KEYNOTE-716 Study. Journal of the American Academy of Dermatology. 91(3). AB116–AB116. 1 indexed citations

Bensimon, Arielle G., et al.. (2023). Cost-Effectiveness Analysis of Pembrolizumab as an Adjuvant Treatment of Resected Stage IIB or IIC Melanoma in the United States. Advances in Therapy. 40(7). 3038–3055. 3 indexed citations

Luke, Jason J., Paolo A. Ascierto, Muhammad Adnan Khattak, et al.. (2023). Pembrolizumab versus placebo as adjuvant therapy in stage IIB or IIC melanoma: Final analysis of distant metastasis-free survival in the phase 3 KEYNOTE-716 study.. Journal of Clinical Oncology. 41(17_suppl). LBA9505–LBA9505. 7 indexed citations

Robert, Caroline, Matteo S. Carlino, Catriona M. McNeil, et al.. (2023). Seven-Year Follow-Up of the Phase III KEYNOTE-006 Study: Pembrolizumab Versus Ipilimumab in Advanced Melanoma. Journal of Clinical Oncology. 41(24). 3998–4003. 63 indexed citations

Samlowski, Wolfram E., Michelle Silver, Shujing Zhang, et al.. (2022). Real-world Clinical Outcomes of Patients with Stage IIB or IIC Cutaneous Melanoma Treated at US Community Oncology Clinics. Future Oncology. 18(33). 3755–3767. 4 indexed citations

Cowey, C. Lance, et al.. (2020). 1116P Real-world clinical outcomes with pembrolizumab (pembro) for treatment of advanced melanoma: Evidence from the United States community oncology setting. Annals of Oncology. 31. S752–S752.

10.

Bensimon, Arielle G., Zheng‐Yi Zhou, Yan Song, et al.. (2019). Cost-effectiveness of pembrolizumab for the adjuvant treatment of resected high-risk stage III melanoma in the United States. Journal of Medical Economics. 22(10). 981–993. 22 indexed citations

11.

Capparelli, Claudia, Timothy J. Purwin, Inna Chervoneva, et al.. (2018). ErbB3 Targeting Enhances the Effects of MEK Inhibitor in Wild-Type BRAF/NRAS Melanoma. Cancer Research. 78(19). 5680–5693. 13 indexed citations

12.

Hammerlindl, Heinz, Dinoop Ravindran Menon, Abdullah Al Emran, et al.. (2017). Acetylsalicylic Acid Governs the Effect of Sorafenib in RAS -Mutant Cancers. Clinical Cancer Research. 24(5). 1090–1102. 15 indexed citations

13.

Chauvistré, Heike, Oliver Keminer, Andrea Sechi, et al.. (2017). Enforced polarization of melanoma cells towards a JARID1B-high phenotype exhausts tumour fitness. RWTH Publications (RWTH Aachen). 15. 4–4.

14.

Amaral, Teresa, Tobias Sinnberg, Friedegund Meier, et al.. (2017). The mitogen-activated protein kinase pathway in melanoma part I – Activation and primary resistance mechanisms to BRAF inhibition. European Journal of Cancer. 73. 85–92. 92 indexed citations

15.

Budina-Kolomets, Anna, Marie R. Webster, Julia I-Ju Leu, et al.. (2016). HSP70 Inhibition Limits FAK-Dependent Invasion and Enhances the Response to Melanoma Treatment with BRAF Inhibitors. Cancer Research. 76(9). 2720–2730. 34 indexed citations

16.

Kim, Hyoung, Erin George, Ryan L. Ragland, et al.. (2016). Targeting the ATR/CHK1 Axis with PARP Inhibition Results in Tumor Regression in BRCA -Mutant Ovarian Cancer Models. Clinical Cancer Research. 23(12). 3097–3108. 234 indexed citations

17.

Fatkhutdinov, Nail, Katrin Sproesser, Clemens Krepler, et al.. (2016). Targeting RRM2 and Mutant BRAF Is a Novel Combinatorial Strategy for Melanoma. Molecular Cancer Research. 14(9). 767–775. 23 indexed citations

18.

Krepler, Clemens, Srinivas K. Chunduru, Molly B. Halloran, et al.. (2013). The Novel SMAC Mimetic Birinapant Exhibits Potent Activity against Human Melanoma Cells. Clinical Cancer Research. 19(7). 1784–1794. 79 indexed citations

19.

Vultur, Adina, Jessie Villanueva, Clemens Krepler, et al.. (2013). MEK inhibition affects STAT3 signaling and invasion in human melanoma cell lines. Oncogene. 33(14). 1850–1861. 73 indexed citations

20.

Schulenburg, Axel, Harald Herrmann, Heidrun Karlic, et al.. (2010). Neoplastic stem cells: Current concepts and clinical perspectives. Critical Reviews in Oncology/Hematology. 76(2). 79–98. 27 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact